RELMADA THERAPEUTICS, INC. Logo

RELMADA THERAPEUTICS, INC.

A clinical-stage biotech developing novel therapies for CNS diseases and oncology.

RLMD | NDAQ

Overview

Corporate Details

ISIN(s):
US75954H1005 (+1 more)
LEI:
Country:
United States of America
Address:
2222 PONCE DE LEON BLVD. 3RD FLOOR, 33134 CORAL GABLES
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative and novel treatments for debilitating disorders. The company's primary research area is central nervous system (CNS) diseases, with a significant focus on therapies for major depressive disorder (MDD), including its lead candidate esmethadone. Relmada is also advancing its development pipeline into oncology, with programs such as NDV-01 for urologic cancers. The company's mission is to create transformative medicines that improve human health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:00
Regulatory News Service
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
English 34.7 MB

Automate Your Workflow. Get a real-time feed of all RELMADA THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RELMADA THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RELMADA THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France ALHYG
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea 187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea 048410
iBio, Inc. Logo
AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.
United States of America IBIO
Ibotta, Inc. Logo
A performance marketing platform offering cash-back rewards to consumers from CPG brands.
United States of America IBTA
ICON PLC Logo
Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.
United States of America ICLR
IDEAYA Biosciences, Inc. Logo
Clinical-stage firm developing precision cancer therapies via synthetic lethality.
United States of America IDYA
IMGT Corporation Limited Logo
Develops a drug delivery platform using ultrasound and nanotech for oncology.
South Korea 456570
IMMERSION CORP Logo
Licenses patented haptic feedback technology for mobile, gaming, and automotive interfaces.
United States of America IMMR
IMMUNIC, INC. Logo
Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.
United States of America IMUX

Talk to a Data Expert

Have a question? We'll get back to you promptly.